Caspase-3 deficiency can limit the efficiency of pro-apoptotic anticancer treatments.
Irofulven (hydroxymethylacyl-
fulvene, HMAF.
MGI 114, NSC 683863) is an
antitumor drug, currently in a Phase III and multiple Phase II trials, which can differentiate between
tumor and normal cells in apoptosis induction. This study investigated whether apoptosis induced by
irofulven requires
caspase-3.
Irofulven action was compared in
breast cancer cells differing in
caspase-3 status: deficient MCF-7 cells and proficient MDA-MB-231 cells and in normal human mammary epithelial cells, HMEC.
Irofulven induces significant, concentration and time-dependent apoptotic DNA fragmentation in
breast cancer cell lines, regardless of
caspase-3 status. After 12, 24 and 48 h incubation at 1 microM
irofulven (approximately 3 x GI50), fragmented
DNA comprised 3.7, 14.1 and 34.6% and 8.4, 12.6 and 20.3% of total
DNA in MCF-7 and MDA-MB-231 cells, respectively. Cell viability (
trypan blue exclusion) remained largely unaffected during the first 24 h but decreased markedly after 48 h, indicating secondary
necrosis. Net losses in cell numbers were apparent at 48 h. Normal HMEC cells were refractory to 1 microM
drug with only approximately 3-9% fragmented
DNA after 12-48 h, although apoptosis was observed at
drug levels >3 microM. The broad-spectrum
caspase inhibitor
Z-VAD-fmk inhibited
irofulven-induced apoptosis of all cell lines at 20 microM with nearly complete abrogation of apoptosis at 100 microM.
Irofulven treatment resulted in marginal
caspase-3 processing in MDA-MB-231 and HMEC cells. These results indicate that whereas the
caspase cascade mediates
irofulven- induced apoptosis,
caspase-3 is dispensable (supported by NIH CA70091 and CA78706).